Updated dailyPubMed-sourced · Research, not medical advice
← Peptide GuidesGrowth Hormone Secretagogues

Sermorelin

Also known as: Sermorelin

A GHRH analog historically used to assess and stimulate growth-hormone release.

⚕️ Educational reference only — not medical advice. Many peptides are not approved for human use and are sold for research purposes only. Always consult a qualified healthcare professional.

Overview

Sermorelin is a shortened GHRH analog that has a history of clinical use, including as a diagnostic agent for growth-hormone function, and is discussed in anti-aging and hormone-optimization contexts.

How It's Thought to Work

It stimulates the pituitary gland to release growth hormone via the GHRH receptor.

What the Research Says

Has more historical clinical familiarity than many research peptides, though modern anti-aging use often outpaces the approved evidence.

Regulatory & Legal Status

Regulatory status has shifted over time; often accessed via compounding pharmacies. Not a general FDA-approved anti-aging therapy.

Safety Considerations

Has known warnings; product source and quality matter. Use under a qualified clinician.

Frequently Asked Questions

What is Sermorelin?

Sermorelin is a shortened GHRH analog that has a history of clinical use, including as a diagnostic agent for growth-hormone function, and is discussed in anti-aging and hormone-optimization contexts.

How does Sermorelin work?

It stimulates the pituitary gland to release growth hormone via the GHRH receptor.

What does the research say about Sermorelin?

Has more historical clinical familiarity than many research peptides, though modern anti-aging use often outpaces the approved evidence.

Is Sermorelin FDA-approved or legal to buy?

Regulatory status has shifted over time; often accessed via compounding pharmacies. Not a general FDA-approved anti-aging therapy.

Is Sermorelin safe? What are the risks?

Has known warnings; product source and quality matter. Use under a qualified clinician.

Want the latest on Sermorelin as it publishes?